Omisirge

Drug Overview

In the clinical field of hematology, achieving rapid immune system recovery is the primary goal following a stem cell transplant. Omisirge is a groundbreaking medication belonging to the Cell Therapy (Stem Cell) drug class. It represents a significant advancement for patients with blood cancers who require a stem cell transplant but may face delays or complications due to the slow recovery times typically associated with traditional umbilical cord blood sources.

As an advanced BIOLOGIC and a form of IMMUNOTHERAPY, Omisirge consists of donor-derived human umbilical cord blood stem cells that have been significantly expanded and enhanced in a laboratory setting. This process allows for a higher concentration of active stem cells to be delivered to the patient, facilitating faster restoration of the body’s ability to produce healthy blood cells.

• Generic Name: omidubicel-onlv
• US Brand Names: Omisirge
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: FDA-approved (April 2023) for use in adult and pediatric patients (12 years and older) with hematologic malignancies.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Omisirge works, one must look at the challenges of traditional umbilical cord blood transplants. While cord blood is a rich source of stem cells, the total number of cells in a single unit is often low. This leads to a long “window of vulnerability” where a patient’s immune system is non-existent, leaving them at high risk for fatal infections and bleeding.

Omisirge utilizes a proprietary technology involving nicotinamide (NAM), a form of vitamin B3. This technology acts as a TARGETED THERAPY at the cellular level during the manufacturing process. At the molecular and hematological level, it works through several key steps:

1. Ex Vivo Expansion: A single unit of cord blood is processed in a laboratory. The CD34+ progenitor cells (the “parent” cells that make all other blood cells) are cultured with nicotinamide.
2. Nicotinamide (NAM) Protection: Usually, when stem cells multiply in a lab, they tend to mature and lose their “stem-ness.” NAM prevents this premature maturation, ensuring the cells remain in a primitive, highly potent state while they multiply.
3. Enhanced Homing and Engraftment: Because the cells remain in this primitive state, they are better at “homing” or finding their way to the bone marrow once infused.
4. Accelerated Hematopoiesis: Once in the bone marrow, these cells begin the process of hematopoiesis (blood cell production) much faster than unmanipulated cells.
5. Hemorrhage Risk Reduction: By accelerating the production of platelets, Omisirge achieves significant hemorrhage risk reduction, shortening the time a patient is at risk for severe internal or external bleeding.

FDA-Approved Clinical Indications

Primary Indication

The primary use of Omisirge is for stem cell transplant recovery in patients with hematologic malignancies (blood cancers). It is specifically indicated for adults and pediatric patients aged 12 and older who are scheduled to receive an umbilical cord blood transplant following a myeloablative conditioning regimen (high-dose chemotherapy or radiation intended to kill cancer cells and clear the bone marrow).

Other Approved & Off-Label Uses

While its primary focus is on blood cancers, Omisirge technology is a subject of interest in broader hematology contexts:

• Leukemia and Lymphoma: Treatment for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Chronic Myeloid Leukemia (CML).
• Myelodysplastic Syndromes (MDS): Providing a transplant option for patients whose bone marrow does not produce enough healthy cells.
• Bone Marrow Failure: While not yet a standard off-label use, research is ongoing regarding its utility in severe aplastic anemia and other non-cancerous bone marrow disorders.

Dosage and Administration Protocols

Omisirge is a highly personalized therapy. It is not a “one-size-fits-all” product; rather, each dose is custom-manufactured for a specific patient using a specific unit of donor cord blood. The final product consists of two fractions: an expanded fraction (the supercharged cells) and a non-expanded fraction (to provide immediate immune support).

Important Adjustments:

• Pre-medication: Patients must receive antihistamines, antipyretics (fever reducers), and sometimes corticosteroids 30 to 60 minutes before infusion to minimize the risk of reactions.
• Conditioning Timing: Omisirge must be infused after the patient has completed their conditioning regimen, typically 24 to 72 hours after the last dose of chemotherapy or radiation.
• Renal and Hepatic Insufficiency: No specific dose adjustments are required for patients with kidney or liver impairment, as this is a cellular therapy rather than a chemically cleared drug. However, these patients require close monitoring for transplant-related toxicities.

Clinical Efficacy and Research Results

Clinical study data from 2020 through 2026 has confirmed that Omisirge significantly shortens the time to immune recovery. In a pivotal Phase 3 clinical trial involving patients with various blood cancers, Omisirge was compared to standard, unmanipulated cord blood.

The numerical data from these trials demonstrated a clear advantage:

• Neutrophil Recovery: The median time to neutrophil recovery (the point where the body can start fighting infections again) was only 12 days for Omisirge patients, compared to 22 days for those receiving standard cord blood.
• Platelet Recovery: Patients achieved a safe platelet count much faster, reducing the number of days spent in the hospital.
• Infection Reduction: Due to the faster white blood cell recovery, there was a significant reduction in the number of severe (Grade 3 or higher) bacterial or fungal infections within the first 100 days post-transplant.

Research consistently shows that by cutting the recovery time nearly in half, Omisirge reduces the overall burden on the patient’s body and lessens the time they must remain in isolation.

Safety Profile and Side Effects

Black Box Warning

Omisirge carries several Boxed Warnings, which are the most serious warnings required by the FDA. These include:

• Fatal Graft-versus-Host Disease (GVHD): A condition where the donor cells attack the patient’s body.
• Engraftment Failure: The risk that the new cells will not grow in the bone marrow.
• Serious Infections: A high risk of infection until the immune system recovers.
• Infusion Reactions: Potential for severe allergic reactions during the administration process.

Common side effects (>10%)

• Pain (various locations)
• Nausea and Vomiting
• Edema (swelling due to fluid retention)
• Fatigue and Weakness
• Constipation or Diarrhea
• Headache

Serious adverse events

• VTE/Thrombosis Risk: Transplant patients are at an increased risk for blood clots due to central venous catheters and immobility.
• Cytokine Release Syndrome (CRS): A severe systemic inflammatory response.
• Organ Toxicity: Damage to the lungs, liver, or kidneys due to the transplant process.

Management Strategies

GVHD is managed through the use of immunosuppressant drugs such as cyclosporine or tacrolimus. If an infusion reaction occurs, the healthcare provider will slow or stop the IV and provide emergency medications like epinephrine. Infection risk is managed by keeping the patient in a specialized “positive pressure” hospital room and providing preventive antibiotics, antivirals, and antifungals.

Research Areas

In the 2026 landscape of hematology, research is focusing on expanding the use of Omisirge to broader populations. Active clinical trials are investigating its safety and efficacy in children under the age of 12. Furthermore, researchers are exploring “haploidentical” combinations, where Omisirge is used alongside a half-matched family donor to further enhance recovery. Other novel delivery systems and “off-the-shelf” expanded cell products are also being developed to reduce the manufacturing time, ensuring that patients can receive their transplant as soon as their cancer is in remission.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

• HLA Typing: To ensure the donor cord blood is a compatible match.
• Organ Function Panels: Comprehensive tests for kidney (creatinine), liver (ALT/AST), and heart (EKG/Echo) function.
• Infection Screening: Testing for HIV, Hepatitis, and CMV.
• CBC (Complete Blood Count): To assess the baseline level of cancer and remaining healthy cells.

Precautions during treatment

• Vigilance for GVHD: Patients and providers must monitor for skin rashes, jaundice (yellowing of the skin/eyes), and severe watery diarrhea.
• Infection Monitoring: Daily monitoring of body temperature; any fever in a transplant patient is considered a medical emergency.
• Transfusion Triggers: Patients will require regular blood and platelet transfusions until the new stem cells are fully functional.

“Do’s and Don’ts” List

• DO follow a strict “neutropenic diet” (avoiding raw or unwashed foods) during the recovery phase.
• DO report any new skin rash or stomach pain to your medical team immediately.
• DO stay in a clean, sanitized environment as directed by your transplant team.
• DON’T miss any follow-up blood tests, as they are the only way to track if the cells are growing.
• DON’T take any herbal supplements or “immune boosters” without consulting your hematologist, as these can trigger GVHD.
• DON’T neglect oral hygiene; mouth sores (mucositis) are common and can lead to serious infections.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Stem cell transplantation is a high-risk medical procedure. Always discuss the risks and benefits of any CELL THERAPY with a specialized transplant hematologist. In case of fever, shortness of breath, or sudden pain following treatment, seek emergency medical care immediately.